Patents by Inventor Benjamin E. Blass

Benjamin E. Blass has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240425487
    Abstract: Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.
    Type: Application
    Filed: December 19, 2023
    Publication date: December 26, 2024
    Inventors: Daniel J. Canney, Benjamin E. Blass, Rong Gao, Magid Abou-Gharbia
  • Patent number: 12172974
    Abstract: Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole. Prodrugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process.
    Type: Grant
    Filed: September 8, 2022
    Date of Patent: December 24, 2024
    Assignees: Biohaven Pharmaceutical Holding Company Ltd., Rutgers, The State University of New Jersey
    Inventors: Garry Robert Smith, Allen B. Reitz, Mark McDonnell, Suzie Chen, Matthew D. Vera, Benjamin E Blass, Jeffrey Claude Pelletier, Venkata N. Velvadapu, Jay Edward Wrobel
  • Publication number: 20240300954
    Abstract: Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of sigma-2 receptor activity.
    Type: Application
    Filed: October 11, 2023
    Publication date: September 12, 2024
    Inventors: Benjamin E. Blass, Daniel J. Canney, Kevin M. Blattner
  • Publication number: 20240300953
    Abstract: Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.
    Type: Application
    Filed: September 27, 2023
    Publication date: September 12, 2024
    Inventors: Benjamin E. Blass, Daniel J. Canney, Kevin M. Blattner
  • Patent number: 11897870
    Abstract: Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.
    Type: Grant
    Filed: April 28, 2020
    Date of Patent: February 13, 2024
    Assignee: Temple University-Of The Commonwealth System Higher Education
    Inventors: Daniel J. Canney, Benjamin E. Blass, Rong Gao, Magid Abou-Gharbia
  • Patent number: 11820774
    Abstract: Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of sigma-2 receptor activity.
    Type: Grant
    Filed: January 21, 2021
    Date of Patent: November 21, 2023
    Assignee: Temple University—Of The Commonwealth System of Higher Education
    Inventors: Benjamin E. Blass, Daniel J. Canney, Kevin M. Blattner
  • Patent number: 11807642
    Abstract: Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.
    Type: Grant
    Filed: December 3, 2021
    Date of Patent: November 7, 2023
    Assignee: Temple University—Of The Commonwealth System of Higher Education
    Inventors: Benjamin E. Blass, Daniel J. Canney, Kevin M. Blattner
  • Publication number: 20230202993
    Abstract: Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole. Prodrugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process.
    Type: Application
    Filed: September 8, 2022
    Publication date: June 29, 2023
    Inventors: Garry Robert Smith, Allen B. Reitz, Mark McDonnell, Suzie Chen, Matthew D. Vera, Benjamin E. Blass, Jeffrey Claude Pelletier, Venkata N. Velvadapu, Jay Edward Wrobel
  • Publication number: 20230112888
    Abstract: Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.
    Type: Application
    Filed: March 31, 2022
    Publication date: April 13, 2023
    Inventors: Daniel J. Canney, Benjamin E. Blass, Kevin M. Blattner, Douglas A. Pippin
  • Publication number: 20230002383
    Abstract: Described herein are new, selective modulators of the 5-HT7 receptor. These selective compounds can be useful for the treatment of CNS and non-CNS indications. Compounds described herein can be selective in targeting 5-HT7 receptors as compared to other receptors and/or by selective targeting 5-HT7 receptors expressed in certain tissues or organs, thereby effective selectivity through a particular partitioning profile of the 5-HT7 modulator.
    Type: Application
    Filed: November 12, 2020
    Publication date: January 5, 2023
    Inventors: Daniel J. Canney, Benjamin E. Blass, Kevin M. Blattner, Douglas A. Pippin
  • Publication number: 20220348581
    Abstract: Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.
    Type: Application
    Filed: December 3, 2021
    Publication date: November 3, 2022
    Inventors: Benjamin E. Blass, Daniel J. Canney, Kevin M. Blattner
  • Publication number: 20220306596
    Abstract: Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.
    Type: Application
    Filed: November 2, 2021
    Publication date: September 29, 2022
    Inventors: Daniel J. Canney, Benjamin E. Blass, Rong Gao, Magid Abou-Gharbia
  • Publication number: 20220306629
    Abstract: Pharmaceutical compositions of the invention comprise functionalized lactam derivatives of formula (I) having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.
    Type: Application
    Filed: May 10, 2019
    Publication date: September 29, 2022
    Inventors: Daniel J. Canney, Benjamin E. Blass, Kevin M. Blattner, Douglas A. Pippin
  • Patent number: 11440893
    Abstract: Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole. Prodrugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process.
    Type: Grant
    Filed: November 23, 2020
    Date of Patent: September 13, 2022
    Assignees: Biohaven Pharmaceutical Holding Company Ltd., Rutgers, The State University of New Jersey
    Inventors: Garry Robert Smith, Allen B. Reitz, Mark McDonnell, Suzie Chen, Matthew D. Vera, Benjamin E. Blass, Jeffrey Claude Pelletier, Venkata N. Velvadapu, Jay Edward Wrobel
  • Publication number: 20220133713
    Abstract: Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of sigma-2 receptor activity.
    Type: Application
    Filed: June 14, 2021
    Publication date: May 5, 2022
    Inventors: Daniel J. Canney, Benjamin E. Blass, Rong Gao, Kevin Blattner
  • Patent number: 11319327
    Abstract: Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.
    Type: Grant
    Filed: September 9, 2020
    Date of Patent: May 3, 2022
    Assignees: Temple University—Of The Commonwealth System of Higher Education, Praeventix, LLC
    Inventors: Daniel J. Canney, Benjamin E. Blass, Kevin M. Blattner, Douglas A. Pippin
  • Patent number: 11220505
    Abstract: Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.
    Type: Grant
    Filed: March 15, 2018
    Date of Patent: January 11, 2022
    Assignee: Temple University-Of the Commonwealth System of Higher Education
    Inventors: Benjamin E. Blass, Daniel J. Canney, Kevin M. Blattner
  • Patent number: 11192871
    Abstract: Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.
    Type: Grant
    Filed: December 12, 2019
    Date of Patent: December 7, 2021
    Assignee: Temple University-Of The Commonwealth System of Higher Education
    Inventors: Daniel J. Canney, Benjamin E. Blass, Rong Gao, Magid Abou-Gharbia
  • Publication number: 20210363145
    Abstract: Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of sigma-2 receptor activity.
    Type: Application
    Filed: January 21, 2021
    Publication date: November 25, 2021
    Inventors: Benjamin E. Blass, Daniel J. Canney, Kevin M. Blattner
  • Publication number: 20210238189
    Abstract: Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.
    Type: Application
    Filed: September 9, 2020
    Publication date: August 5, 2021
    Inventors: Daniel J. Canney, Benjamin E. Blass, Kevin M. Blattner, Douglas A. Pippin